HIV type-1 entry inhibitors with a new mode of action

Antiviral Chemistry and Chemotherapy

Volumn 19, Issue 6, 2009, Pages 243-255

  Fink, Ryan C ^a,b   Roschek Jr , Bill ^b   Alberte, Randall S ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b HerbalScience Group LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CINNAMON EXTRACT; ELDERBERRY EXTRACT; ENFUVIRTIDE; EPIGALLOCATECHIN GALLATE; FLAVONOID; GLYCOPROTEIN GP 41; GREEN TEA EXTRACT; PLANT EXTRACT; PROANTHOCYANIDIN DERIVATIVE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

AIDS PATIENT; ANTIVIRAL ACTIVITY; ARTICLE; CINNAMON; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC 50; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; SAMBUCUS; SEROTYPE; TARGET CELL; TEA; TECHNOLOGY; TIME OF FLIGHT MASS SPECTROMETRY; VIRION; VIRUS INHIBITION;

EID: 77949768125     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020901900604     Document Type: Article

References (45)

1. Fauci AS. HIV and AIDS: 20 years of science. Nat Med 2003; 9:839-843.
2. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
3. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci U S A 1993; 90:1839-1842.
4. Manfredi R, Sabbatani S. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr Med Chem 2006; 13:2369-2384.
5. Matthews T, Salgo M, Greenberg M, Chung J, Demasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004; 3:215-225.
6. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70:461-477.
7. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4:206-220.
8. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. Curr Sci 2004; 86:789-799.
9. Lee KH, Morris-Natschke SL. Recent advances in the discovery and development of plant-derived natural products and their analogs as anti-HIV agents. Pure Appl Chem 1999; 71:1045-1051.
10. Hayashi K, Hayashi T, Ujita K, Takaishi Y. Characterization of antiviral activity of a sesquiterpene, triptofordin C-2. J Antimicrob Chemother 1996; 37:759-768.
11. Mahmood N, Piacente S, Pizza C, et al. The anti-HIV activity and mechanisms of action of pure compounds isolated from Rosa damascena. Biochem Biophys Res Commun 1996; 229:73-79.
12. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacology 1997; 35:229-235.
13. Turville SG, Aravantinou M, Miller T, et al. Efficacy of Carraguard®-based microbicides in vivo despite variable in vitro activity. PLoS One 2008; 3:e3162.
14. Baba M, Nakajima M, Schols D, Pauwel R, Balzarini J, De Clercq E. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res 1988; 9:335-343.
15. Baba M, Snoeck R, Pauwels R, de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 1988; 32:1742-1745.
16. Mahmood N, Pizza C, Aquino R, et al. Inhibition of HIV infection by flavanoids. Antiviral Res 1993; 22:189-199.
17. Kawai K, Tsuno NH, Kitayama J, et al. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol 2003; 112:951-957.
18. Williamson MP, McCormick TG, Nance CL, Shearer WT. Epigallocatechin, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J Allergy Clin Immunol 2006; 118:1369-1374.
19. Roschek B, Jr., Fink RC, McMichael MD, Li D, Alberte RS. Elderberry flavanoids bind to and prevent H1N1 infection in vitro. Phytochemistry 2009. In press.
20. Rees CR, Costin JM, Fink RC, et al. In vitro inhibition of dengue virus entry by p-sulfoxy-cinnamic acid and structurally related combinatorial chemistries. Antiviral Res 2008; 80:135-142.
21. De Bruyne T, Pieters L, Witvrouw M, De Clercq E, Vanden Berghe D, Vlietinck AJ. Biological evaluation of proanthocyanidin dimers and related polyphenols. J Nat Prod 1999; 62:954-958.
22. JEOL. JEOL AccuTOF DART™ Applications Notebook. 3rd ed. Peabody: 2007
23. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-10125.
24. Dorfman T, Popova E, Pizzato M, Gottlinger HG. Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. J Virol 2002; 76:6857-6862.
25. Schaeffer E, Soros VB, Greene WC. Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J Virol 2004; 78:1375-1383.
26. Delaney WE, IV, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004; 48:3702-3710.
27. Fairbanks CA, Wilcox GL. Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J Pharmacol Exp Ther 1999; 288:1107-1116.
28. TACS™ MTT assays: cell proliferation and viability assays. Minneapolis: R&D Systems Inc. 2003; pp. 1-7.
29. Morner A, Bjorndal A, Albert J, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999; 73:2343-2349.
30. Cody RB, Laramee JA, Durst HD. Versatile new ion source for the analysis of materials in open air under ambient conditions. Anal Chem 2005; 77:2297-2302.
31. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41:93-141.
32. Suhnel J. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res 1990; 13:23-39.
33. Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res 2005; 68:66-74.
34. Nagai T, Moriguchi R, Suzuki Y, Tomimori T, Yamada H. Mode of action of the anti-influenza virus activity of plant flavonoid, 5,7,4′-trihydroxy-8- methoxyflavone, from the roots of Scutellaria baicalensis. Antiviral Res 1995; 26:11-25.
35. Alberte RS, Smith RD, inventors; Cerno Biosciences, LLC, assignee. Generation of combinatorial synthetic libraries and screening for novel proadhesins and antiadhesions. United States patent US 7,132,567. 7 November 2006.
36. Perkin Elmer Sciex. The APCI Book, Perkin Elmer Sciex Instruments. 1st ed. Mississauga: Perkin Elmer Sciex 1990.
37. Pramanik BN, Ganguly AK, Gross ML (Editors). Applied electrospray mass spectrometry. 1st ed. New York: Marcel Dekker 2002.
38. Ferreira D, Slade D, Marais JPJ. Flavans and Proanthocyanidins. In Anderson OM, Markhan KR (Editors). Flavonoids: chemistry, biochemistry and applications. Boca Raton: CRC Press LLC 2006; pp. 553-616.
39. Schols D. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res 2006; 71:216-226.
40. Cooper R, Morre DJ, Morre DM. Medicinal benefits of green tea: part I. Review of noncancer health benefits. J Altern Complement Med 2005; 11:521-528.
41. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev 1999; 12:564-582.
42. Roschek B, Jr., Alberte RS. Pharmacokinetics of cyanidin and anti-influenza phytonutrients in an elder berry extract determined by LC-MS and DART TOF-MS. Online Journal of Pharmacology and Pharmacokinetics 2008; 4:1-17.
43. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2:1075-1082.
44. Adams EW, Ratner DM, Bokesch HR, et al. Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem Biol 2004; 11:875-881.
45. Bour S, Geleziunas R, Wainberg MA. The role of CD4 and its downmodulation in establishment and maintenance of HIV-1 infection. Immunol Rev 1994; 140:147-171.